Status and phase
Conditions
Treatments
About
The purpose of this study is to determine ticagrelor combining with low molecular weight heparin is effective and safe during PCI or not.
Full description
Ticagrelor is a new drug compared with clopidogrel. It has a stronger antiplatelet capacity. After PCI,whether using low molecular weight heparin can make patients better prognosis or not, What's more,full amount or half amount low molecular weight heparin?, also investigators want to explore that whether it may lead to more bleeding events.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
300 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal